Chronic obstructive pulmonary disease

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
Wednesday, January 24, 2024

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023.

Key Points: 
  • Gross margin decreased by 50 basis points mainly due to costs associated with a field safety notification for masks with magnets.
  • SG&A expenses improved to 19.1 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
  • ResMed will discuss its second quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Retrieved on: 
Thursday, January 18, 2024

VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.

Key Points: 
  • VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.
  • Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins.
  • NextCure developed an agonist monoclonal antibody (mAb) against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease.
  • The data were presented in a poster presentation at the 2024 Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy:

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Retrieved on: 
Thursday, January 18, 2024

AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.

Key Points: 
  • AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.
  • Korro’s proprietary RNA editing platform, OPERA™, integrates a deep understanding of adenosine deaminase acting on RNA (ADAR) enzymology with expertise in oligonucleotide chemistry, machine learning optimization of oligonucleotides and fit-for-purpose delivery.
  • CHORDs™, or Customized High-fidelity Oligonucleotides for RNA Deamination, are single-stranded, anti-sense oligonucleotides designed to have high target efficiency and specificity by leveraging the pillars of OPERA.
  • The replay is available for 30 days following the January 9, 2024 conclusion of the presentation.

Clinical Study for COPD Patients Opens to Oklahoma County and Pottawatomie County Residents

Retrieved on: 
Monday, January 29, 2024

Despite available treatments like inhalers, many COPD patients still struggle to manage their symptoms effectively.

Key Points: 
  • Despite available treatments like inhalers, many COPD patients still struggle to manage their symptoms effectively.
  • "Our community now has the opportunity to contribute to this crucial research effort, potentially changing the way we approach COPD care."
  • The research study is enrolling for COPD patients 40 to 80 years of age, who have a history of smoking and are at high risk of exacerbations.
  • The local setting provides residents of Choctaw and surrounding communities the option to participate in clinical studies close to home.

AllerVie Health Expands Technology Infrastructure to Prioritize Innovation and Patient Experience

Retrieved on: 
Tuesday, January 23, 2024

"We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.

Key Points: 
  • "We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.
  • Key highlights of digital advancements include:
    In 2023, AllerVie Health expanded its deployment of a state-of-the-art pulmonary function testing solution to 30 clinics nationwide.
  • AllerVie Health implemented a new electronic medical record (EMR) system in 14 clinics across Florida and Georgia during 2023.
  • AllerVie Health's collaboration with a prominent digital health company specializing in respiratory health management broadens the utilization of a portable digital respiratory health tool and app across a more extensive range of clinics within the AllerVie Health network.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

Global Ultrasonic Nebulizer Market to Reach US$ 325.6 Million by 2030, Rising at a CAGR of 5.9% | Report by CoherentMI

Retrieved on: 
Tuesday, January 16, 2024

Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.

Key Points: 
  • Among the end users, hospitals and clinics are expected to dominate the global ultrasonic nebulizer market.
  • Key players operating in the global ultrasonic nebulizer market include Philips Healthcare, Omron, PARI Medical, BD, and Agilent Technologies, among others.
  • Large-volume ultrasonic nebulizers are expected to dominate the global ultrasonic nebulizer market in terms of product type.
  • Overall, the global ultrasonic nebulizer market offers lucrative opportunities in large-volume nebulizers for COPD treatment and the growing demand for home healthcare solutions.

Vida Health Hires Ravi Guha as Chief Financial Officer

Retrieved on: 
Wednesday, January 10, 2024

Virtual cardiometabolic care leader Vida Health announced the addition of Ravi Guha to its executive leadership team as Chief Financial Officer.

Key Points: 
  • Virtual cardiometabolic care leader Vida Health announced the addition of Ravi Guha to its executive leadership team as Chief Financial Officer.
  • “I couldn’t be more thrilled to have Ravi as part of our leadership team at Vida,” said Vida Health CEO Joe Murad.
  • While Heal’s Chief Financial Officer, Mr. Guha spearheaded the company’s transition from a fee-for-service urgent care provider to a value-based primary care model.
  • “It’s an honor to be brought on to Vida to lead financial operations at this inflection point of growth for the company,” said Mr. Guha.

Global Airway Management Devices Market Report 2023-2033: Rising Demand for Advanced Airway Management Devices Driven by Surgical Surges and Chronic Illnesses

Retrieved on: 
Tuesday, January 9, 2024

The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • The escalating demand for airway management devices is primarily propelled by the increasing prevalence of respiratory conditions, particularly Chronic Obstructive Pulmonary Disease (COPD).
  • Geographically, North America is poised to emerge as a major contributor to the growth of the airway management devices market.
  • What are the major market drivers, challenges and opportunities in the global airway management devices market and their case studies?
  • What is the market share of the leading segments and sub-segments of the global airway management devices market?